Literature DB >> 10219777

The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis.

D A Cottrell1, M Kremenchutzky, G P Rice, W Hader, J Baskerville, G C Ebers.   

Abstract

The natural history of primary progressive multiple sclerosis (PP-multiple sclerosis) recently has been defined in a geographically based multiple sclerosis population. For a series of prognostically defined hypothetical entry criteria based upon current trends in presentation to the London Multiple Sclerosis Clinic, we determined the number of patients who would have been trial eligible. Using 23 year mean longitudinal natural history data, we identified the observed rate of deterioration for frequently used trial endpoints. Hypothetical entry criteria were based on the practical considerations which would attend the execution of clinical trials in progressive multiple sclerosis. We then developed a series of sample size tables giving the number of patients with PP-multiple sclerosis and the length of observation that would be required to detect a significant result (P = 0.05) for a 25, 50 and 75% decrease in the median time to progression with 80 or 90% power, with treatment efficacy based upon the ability to slow progression on the disability status score. It is expected that the considerations outlined here will prove useful for both trial design and interpretation of trials in PP-multiple sclerosis which will require multi-centre collaborative efforts.

Entities:  

Mesh:

Year:  1999        PMID: 10219777     DOI: 10.1093/brain/122.4.641

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  11 in total

Review 1.  Prognostic factors for multiple sclerosis: the importance of natural history studies.

Authors:  George C Ebers
Journal:  J Neurol       Date:  2005-09       Impact factor: 4.849

Review 2.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

Review 3.  Primary progressive multiple sclerosis : current and future treatment options.

Authors:  Siobhan M Leary; Alan J Thompson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Chronic restraint stress during early Theiler's virus infection exacerbates the subsequent demyelinating disease in SJL mice: II. CNS disease severity.

Authors:  Erin E Young; Amy N Sieve; Elisabeth G Vichaya; Luis M Carcoba; Colin R Young; Andrew Ambrus; Ralph Storts; C Jane R Welsh; Mary W Meagher
Journal:  J Neuroimmunol       Date:  2010-02-18       Impact factor: 3.478

5.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Authors:  Robert J Fox; Christopher S Coffey; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robin Conwit; Robert Naismith; Akshata Ashokkumar; Robert Bermel; Dixie Ecklund; Maxine Koepp; Jeffrey Long; Sneha Natarajan; Srividya Ramachandran; Thomai Skaramagas; Brenda Thornell; Jon Yankey; Mark Agius; Khurram Bashir; Bruce Cohen; Patricia Coyle; Silvia Delgado; Dana Dewitt; Angela Flores; Barbara Giesser; Myla Goldman; Burk Jubelt; Neil Lava; Sharon Lynch; Augusto Miravalle; Harold Moses; Daniel Ontaneda; Jai Perumal; Michael Racke; Pavle Repovic; Claire Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Gutman; Vijayshree Yadav; Aram Zabeti
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

6.  Mechanisms of normal appearing corpus callosum injury related to pericallosal T1 lesions in multiple sclerosis using directional diffusion tensor and 1H MRS imaging.

Authors:  J Oh; R G Henry; C Genain; S J Nelson; D Pelletier
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-09       Impact factor: 10.154

7.  One year follow up study of primary and transitional progressive multiple sclerosis.

Authors:  V L Stevenson; D H Miller; S M Leary; M Rovaris; F Barkhof; B Brochet; V Dousset; M Filippi; R Hintzen; X Montalban; C H Polman; A Rovira; J de Sa; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-06       Impact factor: 10.154

8.  Heterogeneity in multiple sclerosis: scratching the surface of a complex disease.

Authors:  Giulio Disanto; Antonio J Berlanga; Adam E Handel; Andrea E Para; Amy M Burrell; Anastasia Fries; Lahiru Handunnetthi; Gabriele C De Luca; Julia M Morahan
Journal:  Autoimmune Dis       Date:  2010-12-09

9.  Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.

Authors:  Karen Ann Ribbons; Patrick McElduff; Cavit Boz; Maria Trojano; Guillermo Izquierdo; Pierre Duquette; Marc Girard; Francois Grand'Maison; Raymond Hupperts; Pierre Grammond; Celia Oreja-Guevara; Thor Petersen; Roberto Bergamaschi; Giorgio Giuliani; Michael Barnett; Vincent van Pesch; Maria-Pia Amato; Gerardo Iuliano; Marcela Fiol; Mark Slee; Freek Verheul; Edgardo Cristiano; Ricardo Fernandez-Bolanos; Maria-Laura Saladino; Maria Edite Rio; Jose Cabrera-Gomez; Helmut Butzkueven; Erik van Munster; Leontien Den Braber-Moerland; Daniele La Spitaleri; Alessandra Lugaresi; Vahid Shaygannejad; Orla Gray; Norma Deri; Raed Alroughani; Jeannette Lechner-Scott
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

Review 10.  Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.

Authors:  Jan-Patrick Stellmann; Anneke Neuhaus; Christian Lederer; Martin Daumer; Christoph Heesen
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.